The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use.
Articles
Paws Firmly Planted for Growth in Multibillion-Dollar Pet Health Market
Various public companies are accomplishing the two-fold mission of improving the health of our four-footed friends while giving investors the opportunity to capitalize on a multibillion-dollar industry.
India Globalization Capital, Inc. (NYSE: IGC) Poised to Become Phytocannabinoid Pharmaceuticals Leader
India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures.
Industry Movers Riding the Wave of Bitcoin’s Increasing Value
Bitcoin’s recent climb above the $4,500 mark is just one example of how its market capitalization continues to gain unprecedented reach. (http://nnw.fm/lGp8V) From cannabis to technology, bitcoin has impacted industries far and wide, but analysts believe that the cryptocurrency isn’t done climbing.
ChineseInvestors.com, Inc. (CIIX) Covered in New Report from WallStreet Research™
Before the opening bell, top-ranked independent research firm WallStreet Research™ (WSR) announced the release of a Corporate Profile Analyst Report covering ChineseInvestors.com, Inc. (OTCQB: CIIX).
India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike
Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals.
ABcann Global (TSXV: ABCN) Target Price Set At $2.25 as Coverage is Initiated
PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent.
ChineseInvestors.com, Inc. (CIIX) Discusses Recent Achievements Driving Aggressive Plans for 2017
On Monday, January 30, 2017, Alan Klitenic, the Director of Investor Relations for ChineseInvestors.com, Inc. (OTCQB: CIIX), was interviewed by NetworkNewsWire.
India Globalization Capital, Inc. (NYSE MKT: IGC) Targets Cannabis-Based Pharmaceuticals
India Globalization Capital, Inc. (NYSE MKT: IGC) is a company in transition, now targeting pharmaceutical development in the U.S., while curtailing other businesses such as electronics trading in Hong Kong. IGC long-term plans are to establish and extend its development of phytocannabinoid-based pharmaceutical products to treat diseases such as epilepsy and cachexia.
ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Looks Strong for Investors in Booming Canadian Cannabis Market
ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers.
India Globalization Capital, Inc. (NYSE: IGC) is a First Mover in Cannabinoid Combination Therapies
Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space.
Canadian Cannabis Leaders Sharpen Focus on Increasing Yield, Plant Quality
Growing marijuana in North America, for obvious reasons, has historically been an underground affair. Amid growing legalization in favor of recreational and medicinal use, growing cannabis on mass scale is rapidly becoming a necessity for companies in a burgeoning industry driven by incredible consumer demand.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Enters Research and Development Collaboration with ATERA SAS
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models.
Algae Dynamics Corp. (ADYNF) is “One to Watch”
Algae Dynamics Corp (OTCQB: ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.
ChineseInvestors.com, Inc. (CIIX) Aiming to Help Tackle Epilepsy with a CBD Oil-Based Pharmaceutical
ChineseInvestors.com, Inc. (OTCQB: CIIX), a company in the business of providing Chinese-speaking investors with real-time market analysis, commentary, and educational services, recently announced its goals for 2017, stating that it plans to develop a CBD oil-based pharmaceutical that could help with the major problem of epilepsy in China.